Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Apr;13(4):318-326.
doi: 10.1016/S2213-2600(24)00368-0. Epub 2025 Jan 21.

PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial

Scott M Norberg  1 , Janet Valdez  2 , Scott Napier  3 , Meg Kenyon  3 , Erin Ferraro  3 , Melissa Wheatley  2 , Laura Parsons-Wandell  3 , Stacey L Doran  3 , Amy Lankford  4 , Helen Sabzevari  4 , Douglas E Brough  4 , Jeffrey Schlom  3 , James L Gulley  3 , Clint T Allen  2
Affiliations
Clinical Trial

PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial

Scott M Norberg et al. Lancet Respir Med. 2025 Apr.

Erratum in

Abstract

Background: Recurrent respiratory papillomatosis (RRP) is a rare debilitating condition caused by chronic infection with human papillomavirus (HPV) type 6 or 11. Papillomas develop in the aerodigestive tract, leading to significant voice disturbance and airway obstruction. No systemic treatment currently exists. We aimed to assess the safety and clinical activity of PRGN-2012 in adult patients with RRP treated at the recommended phase 2 dose.

Methods: This was a single-centre, single-arm, phase 1/2 trial. Adult patients aged 18 years or older with RRP who required three or more interventions in the 1 year before treatment received adjuvant PRGN-2012 on day 1 following surgical debulking of disease, and on days 15, 43, and 85. Primary outcome measure was complete response rate, defined as the percentage of patients who did not require an intervention to control RRP in the 12 months after treatment. Safety outcomes included treatment-related adverse events. This study is registered ClinicalTrials.gov (NCT04724980).

Findings: From March 16, 2021, to June 1, 2023, 38 patients were enrolled and received the 12-week treatment course. Among the 35 patients treated at the recommended phase 2 dose of 5×1011 particle units, 18 (51%) of 35 patients had a complete response (95% CI 34-69) with the median duration of complete response yet to be reached. Adverse events were mild and included grades 1-2 injection site reaction (34 [97%] of 35), fatigue (28 [80%] of 35), chills (25 [71%] of 35), and fever (24 [69%] of 35).

Interpretation: PRGN-2012 treatment resulted in complete response in 51% of the patients treated and was safe. Based on these positive pivotal study results, a biologics license application to the US Food and Drug Administration (FDA) is planned, positioning PRGN-2012 to be an FDA-approved medical treatment for adult patients with RRP.

Funding: National Institutes of Health.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests JS, JLG, and CTA are tenured senior investigators (equivalent to full professor) at the National Institutes of Health. AL, HS, and DEB are employees of Precigen and report stock or stock options in the company. AL reports support for attending meetings and travel by Precigen. DEB has a patent related to this work titled “Human papillomavirus vaccines and uses of the same for HPV associated diseases” with patent number WO2022/115470. HS reports other related patents planned, issued, or pending. JS reports that National Cancer Institute (NCI) has a Cooperative Research & Development Agreement with Precigen. All other authors declare no competing interests.

References

    1. Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowitz R, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis. 2018. Jan 4;217(2):208–12. - PubMed
    1. Meites E, Stone L, Amiling R, Singh V, Unger ER, Derkay CS, et al. Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021. Sep 7;73(5):885–90. - PMC - PubMed
    1. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. The Laryngoscope. 2008. Jul;118(7):1236–47. - PubMed
    1. Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg. 1999. Jul;125(7):743–8. - PubMed
    1. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995. Dec;121(12):1386–91. - PubMed

Publication types

Supplementary concepts

Associated data

LinkOut - more resources